Medisca Expands Strategic Partnerships to Drive Patient Access to Critical Medications
27.7.2023 14:55:00 EEST | Business Wire | Press release
Medisca has announced the expansion of a network of strategic partnerships aimed at securing and stabilizing worldwide access to high quality active pharmaceutical ingredients (APIs) for the preparation of essential medications. This mission started with the exclusive partnership for Thyroid USP in 2021, and has now expanded to include Progesterone USP (Special Micronized), Testosterone USP (Micronized), Diclofenac Sodium USP, and Ketamine Hydrochloride USP.
In recent years, Medisca has seen significant increases in the demand for these APIs with commercial drug shortages and the need for qualified products and transparency documented as the primary causes. By actively engaging in strategic partnerships, Medisca reinforces its position as a true Partner In Wellness and driver in securing high-quality product supply for the pharmaceutical compounding and healthcare industries.
“We are steadfast in our commitment to promoting pharmaceutical compounding as a legitimate, effective, and essential solution for healthcare providers working to overcome challenges in medication accessibility and looking to provide transformative options for personalized patient care,“ said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “To achieve this we continue our mission to forge partnerships with leaders in API manufacturing that are unified by a common commitment to quality, consistency, and value,” continued Danopoulos
In order to vet the right partners, Medisca conducts thorough due diligence to ensure the highest quality measures are met at the source. All partners undergo a rigorous vendor qualification program with proof of FDA registration, quality agreements in place, and testing performed to verify the quality of the product including, full USP compendial testing, elemental impurity testing, residual solvent testing, and particle size testing for micronized products.
Leveraging these strong partnerships in API manufacturing and collaborating closely with government authorities, Medisca is able to support market access to essential APIs and address the critical needs of healthcare providers and patients across the globe.
About Medisca
Medisca is a global corporation with locations throughout North America, Australia, and Europe, that contributes to healthcare by leveraging strong partnerships that deliver customized solutions with an unwavering commitment to quality and innovation. Backed by 30+ years and a strong foundation in pharmaceutical compounding supply, Medisca is a business-to-business company that delivers comprehensive offerings by providing value, consistency, responsiveness, and loyalty. As Partners in Wellness, Medisca offers an unfailing devotion to improving lives across a multitude of needs and people. For more information visit www.medisca.com and follow us on LinkedIn, Facebook, Twitter, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727308061/en/
Contact information
Gayle Padvaiskas
Vice President, Global Marketing
Medisca
gpadvaiskas@medisca.com
1-800-665-6334
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3.9.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026 and consisted of options to purchase an aggregate of 280,600 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 133,500 shares. The options have an exercise price per share equal to $13.24, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restr
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®3.9.2026 23:30:00 EEST | Press release
Mainstay Medical Holdings plc today announced the publication of the two-year assessment results from the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable chronic low back pain. The data show continued improvements in back pain-related disability, pain and quality of life in the ReActiv8 treatment group, and improvements after one year of ReActiv8 therapy in the crossover group that were indistinguishable from the improvements shown by the treatment group at their one-year assessment. The results were published in The Spine Journal, and the article is available free of charge here: https://doi.org/10.1016/j.spinee.2026.07.006. The study included 203 patients, with 99 randomized into the treatment arm and 104 randomized into the control arm. Patient-reported outcomes were collected at regular intervals to the one-year primary endpoint assessment, at which time the patients in the control arm were offered implantation with the ReActiv8 system. Eighty-three p
Lenovo Advances Hybrid AI Across New Personal and Enterprise Technology3.9.2026 19:00:00 EEST | Press release
Today at Lenovo™ Innovation World during IFA 2026, Lenovo unveiled a new portfolio of personal and enterprise technology, showing how its Hybrid AI strategy is moving from vision to practical experiences across devices, infrastructure, services, and the everyday moments that connect them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903555953/en/ Lenovo Innovation World at IFA 2026 The announcements bring together Lenovo’s “one personal AI, multiple devices” approach with enterprise technology that helps organizations turn data into insights and value. They span personal AI across PCs, smartphones, tablets, and wearables; creator and consumer devices that adapt to different ways of working and expressing ideas; and business technology built for AI-enabled productivity, collaboration, security, and scale. Lenovo also demonstrated how design and form factor remain central to making technology more useful: from high-perfor
Kaltura and Verimatrix Partner to Strengthen Security for OTT and Cloud TV Services3.9.2026 18:45:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903384589/en/ Kaltura (Nasdaq: KLTR), the Agentic Digital Experience company, and Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced a strategic partnership designed to provide enhanced protection for OTT and Cloud TV services. The partnership brings together Kaltura's scalable Cloud TV platform and Verimatrix's Digital Rights Management (DRM) and security capabilities. The joint solution, as part of Kaltura’s Marketplace, helps Telco’s, broadcasters, and media companies securely deliver premium live and on-demand content across a wide range of devices and operating systems. Demand for advanced content protection has grown, and Kaltura's Cloud TV footprint has expanded across Telco’s, operators, broadcasters, and media companies. Partnering with Verimatrix, a recognized leader in content pro
Bahrain Signs its Participation Contract for Expo 2030 Riyadh3.9.2026 18:45:00 EEST | Press release
The Kingdom of Bahrain has signed its Participation Contract for Expo 2030 Riyadh, marking a new phase in preparations for its participation in the World Expo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903144412/en/ His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President of the Bahrain Authority for Culture and Antiquities, and Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, at the ceremony. The agreement provides the formal framework for Bahrain’s participation in Expo 2030 Riyadh, enabling preparations to advance across the key organizational and operational aspects of its presence throughout the six-month event, including the development of its pavilion, programmes and visitor experiences. The Participation Contract was signed in Bahrain by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, on behalf of Expo 2030 Riyadh, and His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom